LRRK2 (Leucine-Rich Repeat Kinase 2)

LRRK2 (Leucine-Rich Repeat Kinase 2)

Overview

LRRK2 (Leucine-Rich Repeat Kinase 2)

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">LRRK2</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>LRRK2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Leucine-Rich Repeat Kinase 2</td>
</tr>
<tr>
<td class="label">Gene Location</td>
<td>12q12 (chromosome 12)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Serine/threonine kinase</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q5S007" target="_blank">Q5S007</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">View in Atlas</a></td>
</tr>
</table>

LRRK2 (Leucine-Rich Repeat Kinase 2) is a large, multi-domain enzyme that functions as both a kinase and a GTPase. It is the most commonly mutated gene in familial [Parkinson's disease](/diseases/parkinsons-disease) and is also a risk factor for sporadic PD and other neurodegenerative conditions. LRRK2 regulates multiple cellular processes including vesicle trafficking, autophagy, lysosomal function, and immune responses. Pathogenic mutations typically increase kinase activity, leading to neuronal dysfunction and degeneration.

Structure and Domains

LRRK2 is a large 286 kDa protein (2,527 amino acids) with a complex multi-domain architecture:

• ARM (Armadillo) repeats: Protein-protein interaction domain at N-terminus
• ANK (Ankyrin) repeats: Additional scaffolding domain
• LRR (Leucine-Rich Repeat): Regulatory domain
• ROC (Ras of Complex): GTPase domain that binds and hydrolyzes GTP
• COR (C-terminal of ROC): Dimerization domain
• Kinase domain: Serine/threonine kinase catalytic core
• WD40 domain: C-terminal protein interaction domain

Cellular Functions

Vesicle Trafficking and Membrane Dynamics

LRRK2 localizes to membranous structures and regulates:

• Endocytic vesicle trafficking
• Golgi dynamics and secretory pathways
• Synaptic vesicle endocytosis
• Trans-Golgi network (TGN) function

Autophagy and Lysosomal Function

LRRK2 regulates autophagy at multiple levels:

• Autophagosome formation and maturation
• Lysosomal positioning and acidification
• Autophagy-lysosome fusion
• Mitophagy (selective autophagy of mitochondria)

Immune Function

LRRK2 is highly expressed in immune cells (macrophages, microglia) and modulates:

• Inflammatory responses to pathogens
• Cytokine production
• Phagocytosis
• Interferon signaling

Role in Parkinson's Disease

Genetic Mutations

LRRK2 mutations account for:

• 5-6% of familial Parkinson's disease
• 1-2% of sporadic cases globally
• Up to 40% of PD cases in certain populations (Ashkenazi Jews, North African Arabs)

• R1441C/G/H (ROC domain)
• Y1699C (COR domain)
• I2020T (kinase domain)

Pathogenic Mechanisms

Increased LRRK2 kinase activity causes:

• Excessive Rab protein phosphorylation
• Impaired autophagy and lysosomal clearance
• Mitochondrial dysfunction and impaired mitophagy
• Disrupted vesicle trafficking
• Enhanced susceptibility to alpha-synuclein toxicity
• Neuroinflammation via microglial activation

Clinical Features

LRRK2-associated PD is clinically similar to idiopathic PD:

• Asymmetric onset of motor symptoms (tremor, rigidity, bradykinesia)
• Good response to levodopa therapy
• Age of onset typically 50s-60s (range 30s-80s)
• Generally slower progression than sporadic PD
• Lower likelihood of cognitive impairment

Therapeutic Targeting

LRRK2 is one of the most promising drug targets in Parkinson's disease:

LRRK2 Kinase Inhibitors

Multiple selective LRRK2 kinase inhibitors are in clinical development:

• DNL201 (Denali Therapeutics) - Phase 1 completed
• DNL151 (Denali Therapeutics) - Phase 1b ongoing
• BIIB094 (Biogen) - Development discontinued
• Multiple preclinical compounds

• Achieving CNS penetration
• Avoiding dose-limiting toxicity (lung abnormalities in primates)
• Determining optimal degree of kinase inhibition

Antisense Oligonucleotides

ASO-mediated reduction of LRRK2 expression is being explored as an alternative approach, particularly for mutation carriers.

Small Molecule Correctors

Compounds that normalize LRRK2 GTPase activity or prevent pathogenic interactions are in early research.

Related Entities

• [Parkinson's Disease](/diseases/parkinsons-disease) - Primary disease association
• [Alpha-Synuclein](/proteins/alpha-synuclein) - Interacts with LRRK2 pathways
• [Rab GTPases](/proteins/rab-gtpases) - Direct phosphorylation substrates
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons) - Primary vulnerable cell type
• [Autophagy](/mechanisms/autophagy) - Cellular process regulated by LRRK2
• [Microglia](/cell-types/microglia) - Express high LRRK2; role in neuroinflammation

References

External Links

• [UniProt: LRRK2](https://www.uniprot.org/uniprot/Q5S007)
• [OMIM: LRRK2](https://www.omim.org/entry/609007)
• [Michael J. Fox Foundation: LRRK2](https://www.michaeljfox.org/understanding-parkinsons/living-with-pd/topic.php?genetics-lrrk2)
• [PubMed: LRRK2 therapeutics](https://pubmed.ncbi.nlm.nih.gov/?term=LRRK2+inhibitor+clinical)

Pathway Diagram

The following diagram shows the key molecular relationships involving LRRK2 (Leucine-Rich Repeat Kinase 2) discovered through SciDEX knowledge graph analysis: